The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia

Medical Journal of Malaysia

Volumn 67, Issue 1, 2012, Pages 39-44

  Ruzanna, Z Z ^a   Ong, L Y ^b   Cheah, Y C ^b   Fairuz, A ^a   Marhani, Midin ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b Hospital Bahagia Ulu Kinta   (Malaysia)

Author keywords

Antipsychotics; Dyslipidaemia; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SULPIRIDE;

ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SOCIOECONOMICS; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 84859376795     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Allebeck P. Schizophrenia: A life-shortening disease. Schizophr Bull. 1989; 15(1): 81-9.
2. Brown S, Inskip, H. & Barraclough, B. Causes of the excess mortality in schizophrenia. British J Psychiatry. 2000; 177: 212-7.
3. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment. The metabolic syndrome. Life Sciences. 2002: 239-57.
4. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001; 35: 196-202.
5. Van Gaal LF. Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity. Europ Neuropsychopharmacol. 2006; 16: 142-8.
6. Ryan MC, Collins, P. & Thakore, J.H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry. 2003; 160: 284-9.
7. Jow GM, Yang TT, Chen CL. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord. 2006; 90: 21-7.
8. Pato C, Esop R, Young C, Taylor D. Obesity, dyslipidaemia and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatric Scand. 2004; 110: 299-305.
9. Saari K, Koponen H, Laitinen J, Jokilinen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: A general population-based birth Cohort study. The Journal of Clinical Psychiatry. 2004b; 65(4): 547-50.
10. Ministry of Health Malaysia. National Mental Health Registry. Ministry of Health Malaysia; 2003.
11. Casey DE. Dyslipideamia and Atypical Antipsychotic Drugs. J Clin Psychiatry. 2004; 65: 27-35.
12. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsyhotic drugs in Taiwan. Schizophr Res. 2005; 80: 585-90.
13. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophr Res. 2004; 71: 195-212.
14. Koro C, Fedder D, L'Italien G, Weiss S, Laurence SM, Kreyenbuhl J, Revicki D et al. An assessment of the independent effects of clozapine and risperidone exposure on the risk of hyperlipidaemia in schizophrenia patients. Arch Gen Psychiatry. 2002; 59: 1021-6.
15. Lambert TR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Austr. 2003; 178: S67-S70.
16. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006; 163(10): 1821-5.
17. Ucok A, Gaebek W. Side effect of atypical antipsychotic: a brief overview. World Psychiatry; 2008. 2008. p. 58-62.
18. Nasrallah H, Newcomer JW. Atypical antipsychotic and metabolic dysregulation. J Clin Psychopharmacol. 2004; 24(1): 7-14.
19. Rettenbacher M. Disturbance of glucose and lipid metabolism during treatment with new generation antipsychotic. Curr OpinPsychiatry. 2005; 18(2): 175-9.
20. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I et al. Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine. Am J Psych. 2002; 159: 1055-7.
21. Aida MA. Prevalence of depression/anxiety and quality of life in patient with traumatic brain injury: Universiti Kebangsaan Malaysia; 2008.
22. Norharlina B. Association between menstrual cycle and deliberate self harm: A case control study: Universiti Kebangsaan Malaysia; 2005.
23. Bech P, Malt UE, Dencker SJ, Ahlfors UG, Elgen K, Lewander T, Lundell A Mc et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatric Scand. 1993; 87(Suppl. 372).
24. Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome. Diabetes Voice. 2005; 50(3): 31-3.
25. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Liebermen JA. Low rates of treatment for hypertension, dyslipidaemia and diabetes in schizophrenia. Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86: 15-22.
26. Zambahari R. Trends in cardiovascular diseases and risk factors in Malaysia. International Congress Series; 2004. 2004. p. 446-9.
27. De Hert MA, van Winkel R, van Eyck D, Hanssens L, Wampers M, Scheen A, Peusken J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83: 87-93.
28. Schorr SG, Sloof CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009.
29. Kontis D, Psaras RM, Papadopolous S, Lia E, Papageorgiou S, Reperidis S, Karouzoa C. Serum lipid levels in schizophrenia and bipolar disorder relapse. Eur Psychiatry. 2008; 23: 81-191.
30. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum insulin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003; 64(5): 598-604.
31. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment; the effect of concurrent b-adrenergic antagonist treatment. Schizophr Res. 2002; 59: 49-57.
32. Domon SE, Webber JC. Hyperglycemia and hypertriglycerideamia secondary to Olanzapine. J Child Adolesc Psychopharmacol. 2001; 11: 285-8.
33. Stahl SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz; 2000.
34. Meyer J, Koro C. The effects of antipsychotic therapy on serum lipid: a comprehensive review. Schizophr Res. 2004; 70: 1-71.
35. De Hert M, Scheurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of metabolic syndrome in first episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008; 101: 295-303.
36. Allison DB, Mentore JL, Moonseong H, Linda PC, Joseph CC, Ming CI, Peter JW. Antipsychotic-induced weight-gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 72: 1686-96.
37. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999; 29(3): 697-701.
38. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr Res. 2005; 76: 135-57.
39. Rampal L, Rampal S, Azhar MZ. A national study on prevalence and factors associated with smoking among 17,426 Malaysians aged 18 years and above. The 13th World Conference on Tobacco OR Health; 2006. 2006.
40. Ng TKW, Teh CB, Vidyadaran MK, Tee ES, Thong ML, Kandiah M, Khalid AH. A critical evaluation of high density lipoprotein cholesterol as an index of coronary artery disease risk in Malaysians. Mal J Nutr. 1997;3:61-70.
41. Ministry of Health M. Clinical Practice Guideline on Prevention of Cardiovascular Disease in Women. 1 ed: Ministry of Health, Malaysia; 2008.